Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Derralynn Hughes et al.|New England Journal of Medicine|2016Cited by 555
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Joel Charrow et al.|Journal of Medical Genetics|2015Cited by 363
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Reynir Arngrı́msson et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortíz, David G. Warnock, Juan Politei et al.|Journal of Medical Genetics|2016Cited by 147